FDA’s Dr. Janet Woodcock writes about regimen development in the New England Journal of Medicine, noting that it is an important approach for drug development of therapies that can impact the human condition. She specifically calls out the need for information sharing through nonprofit groups and initiatives. Click here to read the article.
A new report from the Treatment Action Group (TAG), a research and policy think tank, and the Global Stop TB Partnership, reveals that in 2009 – the last year for which full data are available – the world invested just $614 million in tuberculosis research and development.
According to a paper published today in The Lancet, there is unprecedented progress in the development of the global tuberculosis (TB) drug pipeline with 10 drug candidates currently in clinical development. The paper was written by a team of renowned international experts led by Zhenkun Ma, Ph.D., Chief Scientific Officer for the TB Alliance, a not-for-profit organization accelerating the discovery and development of new TB drugs.